A Substudy of the Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Mar 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a method called acute normovolemic hemodilution (ANH) during bone tumor surgery. The goal is to see if this technique can help improve hemoglobin levels (which is important for healthy blood) after surgery when combined with a special fluid management strategy. Researchers believe that preventing low blood levels during and after surgery could lead to fewer complications and shorter hospital stays for patients.

To participate in this trial, you need to be between 18 and 75 years old and scheduled for surgery to remove a bone tumor. You should also have a preoperative hemoglobin level of at least 11 g/dL. However, if you are using a tourniquet during surgery, have certain health conditions, or are pregnant, you may not be eligible. If you join the study, you'll receive treatment based on the trial's specific guidelines, which may help improve your recovery after surgery. Overall, this trial aims to gather important information that could benefit future patients undergoing similar procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. age 18 to 75 years;
• • 2. undergoing elective bone tumor resection surgery;
• • 3. preoperative hemoglobin ≥11 g/dL;
• Exclusion Criteria:
• • 1. using a tourniquet;
• • 2. palliative operation or minimally invasive surgery;
• • 3. BMI\<18.5 or \>30Kg/m\^2;
• • 4. international normalized ratio (INR) \>1.5 or platelet count \<100 × 10\^9/L;
• • 5. cardiopulmonary insufficiency;
• • 6. hepatic and renal dysfunction;
• • 7. active infectious disease;
• • 8. allergy to succinyl gelatin;
• • 9. pregnancy;
• • 10. declined participation in the study or declined blood transfusion